...
The analysis dataset includes treatment and demographic information drawn from the ADSL. In this example, we only show some of the required variables plus important stratification variables from ADSL. One variable mentioned body surface area (BSA), can be computed and added to ADSL. However, since the subjects are children, their body surface area changes over time. Therefore it would probably be better to have a separate dataset to capture this over time. In this example, we will show one variable for BSA with the variable "Baseline Body Surface Area (m2)" which can be added to ADSL.
Questions.
Is screening considered visit 1, or is it to include the subject into the study? SDTM team agreed to change to VISIT 1 instead of SCREENING.
...
Should i use Male and 6 years? please advise.
Analysis Datasets
Below is the table of The table below presents the analysis datasets and unique parameters created generated for the this example. The Subject Level Analysis Dataset (ADSL is required as part of the process of creating the ) is a necessary component in the creation process of subsequent analysis datasets for human trials.
The ADSL includes incorporates demographics, treatment groups, study dates, and stratification variables. For In this example, the ADSL is not shown other than displayed directly but serves as a source for standard ADaM variables. See Additional information on this can be found in Section 2.3.1 of the ADaM Implementation Guide (ADaMIG) v1.3 for additional information.
The ADCVEF is a dataset capturing only the tests required for dataset selectively captures tests pertinent to this analysis, selecting for specifically those with CVTESTCD equal to "LVEF_C" or "RVEF_C". The relationship dataset RELREC shows the datset relationshipsillustrates the connections between datasets. There is exists a many-to-one relationship between the cardiovascular tests from (CV) and the laboratory data collected at during the same visits. Therefore by subsetting the LB with LBLNKID not missing, this selects the laboratory data that can be merged with CV by USUBJID and VISIT (or USUBJID and AVISIT in ADaM) In ADaM analysis datasets we can also use a windowing strategy to select the laboratory draw closest to that visit to merge with CV which is computed in AVISIT in which case all LB records would be kept for the tests of interest.
ADCVNTRP ADLBNTRP is a subset of LB selecting for LBTESTCD equal to "BNPPRONT", and LBLINKID not missing. In this case, many lab draws may occur throughout the year, but we are only interested in the ones linked to a specific visit. By subsetting the Laboratory Results (LB) dataset with LBLNKID not missing, we can select laboratory data that aligns with CV data and sort using USUBJID and VISIT. If LBLNKID were not available, a windowing strategy could be employed to select the laboratory draw closest to that visit for merging with CV, computed in AVISIT.
ADCMRI is an efficacy analysis dataset with only a few records for more complex modeling of changes in ejection fraction plus the ProB-type test results. It is a Basic Structure dataset with additional variables added from ADCVEF.
Definexmltable |
---|
Multiple | true |
---|
Level | Dataset |
---|
Purpose | Analysis |
---|
|
Dataset Name | Dataset Description | Class of Dataset | Structure | Location | Keys | Documentation |
---|
ADSL | Subject-Level Analysis Dataset | SUBJECT LEVEL ANALYSIS DATASET | adsl.xpt | One record per subject | USUBJID | ADaMIG v1.3 section 3.1.1 | ADCVNTRP | Cardiac Ejection Fraction and NTproBNP Analysis Dataset | BASIC DATA STRUCTURE | One record per subject per analysis visit per parameter. | adcvntrp.xpt | USUBJID, AVISITN, PARAMCDPARAMN | Analysis Analysis Dataset | ADCMRI | Cardiac Magnetic Resonance Imaging Measurements Summary Analysis Dataset | BASIC DATA STRUCTURE | One record per subject per analysis visit per parameter. | adcmrief.xpt | USUBJID, AVISITN, PARAMCDPARAMN | |
|
Definexmltable |
---|
Dataset | ADCVNTRP |
---|
Level | Value |
---|
Purpose | Analysis |
---|
OID | AVAL |
---|
|
Dataset | Variable | Where | Type | Origin | Derivation/Comment |
---|
ADCVNTRP | AVAL | PARAMCD = " LVEFC" | Num | Predecessor | Set to CV. CVSTRESN where CV.CVTESTCD ="LVEF_C". | ADCVNTRP | AVAL | PARAMCD = "RVEFC" | Num | Predecessor | Set to CV. CVSTRESN where CV.CVTESTCD ="RVEF_C". | ADCVNTRP | AVAL | PARAMCD = "BNPPRONT" | Num | Predecessor | Set to LB.LBSTRESN where LB.LBTESTCD = "BNPPRONT"ADCMRI |
|
Analysis Datasets
The following are subsequent section outlines the data structures for the example ADaM datasets. Note that the In this example, columns for derived variables, BASE, and CHG, PCHG and CHGCAT1 have been added for the efficacy analysis of fto facilitate analyses of efficacy endpoints. The Specifically, example demographics demographic data for ADSL were created for an 8 year old male child. Also, BSA at baseline (BSABASE), an example of a custom variable, was added from ADSL. The ADaM standard only suggests variable order, so the demographics and treatment variables have been put at the end, so that the variables of interest are shown at the beginning right of the dataset. Since we are combining two SDTM domains into one analysis dataset, some variables unique to LB will be blank for records from CV.
Definexmltable |
---|
Dataset | ADCV |
---|
Level | Variable |
---|
Purpose | Analysis |
---|
Name | Variable |
---|
|
Variable Name | Variable Label | Type | Codelist/Controlled Terms/Format | Source | Derivation/Comment |
---|
STUDYID | Study Identifier | Char |
| CV.STUDYID |
| USUBJID | Unique Subject Identifier | Char |
| | Select for records with RE data. | ASEQ | Analysis Sequence Number | Num |
| CV.CVSEQ | Number records 1 to n after sorting by keys. | BSABASE | Body Surface Area (m2) at Baseline | Num |
| ADSL.BSABSEBSABASE | Compute in ADSL where VS.VSTESTCD = "BSA". | PARAM | Parameter | Char | Left Ventricular Ejection Fraction, Calculated (%) Right Ventricular Ejection Fraction, Calculated (%) N-Terminal ProB-type Natriuretic Peptide (pg/mL) |
| For tests from CV, set to the values of CV.CVTEST plus CV.CVTESTU with spaces and parentheses as shown. For tests from LB, set to the value of LB.LBTEST plus LB.LBTESTU with spaces and parentheses as shown. | PARAMCD | Parameter Code | Char | LVEFC RVEFC BNPPRONT
|
| If CV.CVTESTCD = "LVEF_C" then PARAMCD = "LVEFC" If CV.CVTESTCD = "RVEF_C" then PARAMCD = "RVEFC". If LB.LBTESTDC = "BNPPRONT" then PARAMCD = "BNPPRONT. Note: for this example dataset, select the records where the test values shown above are included. | PARAMN | Parameter Number | Num |
|
| Number PARAMCD as follows: "LVEFC = 1" "LVRFC = 2" BNPPRONT = "3" | AVAL | Analysis Value | Num |
|
| See Parameter Value List | AVISIT | Analysis Visit | Char |
|
| If CV.VISIT = "VISIT 1" then AVISIT = "Visit 1 (Baseline)". Else if CV.VISIT = "VISIT 6" then AVISIT = "Visit 6 (1 Year)". | AVISITN | Analysis Visit (N) | Num |
|
| Set to value of CV.VISITNUM or LB.VISITNUM | VISIT | Visit | Num |
| CV.VISIT LB.VISIT |
| ADT | Analysis Date | Num | date9. |
| Date portion of CV.CVDTC or LB.LBDTC converted to numeric and displayed in a format such as date9. | ABLFL | Baseline Record Flag | Char | Y |
| If CV.VISIT = 1 then ABLFL = "Y". | BASE | Baseline Value | Num |
|
| Set BASE to AVAL from the record for that subject and parameter where ABLFL = "Y". Populate BASE for additional visits by merging by USUBJID and ADT. (Or by AVISIT if ADT varies for labs, and windowing is applied to select record closest to the visit) | CHG | Change from Baseline | Num |
|
| Compute CHG = AVAL - BASE for that record. Only compute for post-baseline records. | PCHG | Percent Change from Baseline | Num |
|
| Compute PCHG = (CHG / BASE) * 100. Only compute for post-baseline records. | CHGCAT1 | Change from Baseline Category 1 | Char | >1.0 g(IU/dLL); <=1.0 g/dL(IU/L) |
| Categorise the value of CHG | LBSTRNRLO | Reference Range Lower Limit-Std Units | Num |
| LB.LBSTRNRLO |
| LBSTRNHI | Reference Range Upper Limit-Std Units | Num |
| LB.LBSTRNHI |
| LBNRIND | Reference Range Indicator | Char | (NRIND) | LB.LBNRIND |
| TRT01P | Planned Treatment for Period 01 | Char | "Treatment A" | ADSL.TRT01P | For this example we are using "Treatment A". In a Real World Evidence study this could be non-treatment related, e.g. "Group A". | ITTFL | Intent-to-Treat Population Flag | Char | Y; N | ADSL.ITTFL | Pick other population? POSSIBLE RWE STUDY | AGE | Age | Num |
| ADSL.AGE |
| AGEU | Age Units | Char | (AGEU) | ADSL.AGEU |
| SEX | Sex | Char | (SEX) | ADSL.SEX |
| SRCDOM | Source Data | Char | CV; LB |
| Set to the SDTM domain name that relates to the analysis value. | SRCSEQ | Source Sequence Number | Num |
| CV.CVSEQ LB.LBSEQ | Set to the SDTM domain sequence number that relates to the analysis value. |
|
...
Dataset wrap |
---|
|
Rowcaps |
---|
Rows 1-4: | Show the baseline CMR ejection fraction measurements for participant 101 at VISIT 1. | Row 5: | Shows the baseline NTProbTest for participant 101 at VISIT 1. | Rows 6-9: | Show the CMR ejection fraction measurements for participant 101 at VISIT 6. | Row 10: | Shows the NTProbTest for participant 101 at VISIT 6. |
|
Dataset2 |
---|
| Row | STUDYID | USUBJID | ASEQ | BSABASE | PARAM | PARAMCD | PARAMN | AVAL | AVISIT | AVISITN | VISIT | ADT | ABLFL | BASE | CHG | PCHG | CHGCAT1 | LBSTRNRLO | LBSTRNRHI | LBNRIND | TRT01P | ITTFL | AGE | AGEU | SEX | SRCDOM | SRCSEQ |
---|
1 | DMD-EFLGE | DMD-EFLGE-101 | 1 | 0.65 | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 1 | 67 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 67 |
|
|
|
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 3 | 2 | DMD-EFLGE | DMD-EFLGE-101 | 2 | 0.65 | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 2 | 74 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 74 |
|
|
|
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 7 | 3 | DMD-EFLGE | DMD-EFLGE-101 | 3 | 0.65 | N-Terminal ProB-type Natriuretic Peptide (IU/L) | BNPPRONT | 3 | 40 | Visit 1 (Baseline) | 1 | VISIT 1 | 16May2022 | Y | 40 |
|
|
| 100 | 40 | NORMAL | Treatment A | Y | 8 | YEARS | M | LB | 1 | 4 | DMD-EFLGE | DMD-EFLGE-101 | 4 | 0.65 | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 1 | 60 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 |
| 67 | -7 | -10.447761 |
|
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 11 | 5 | DMD-EFLGE | DMD-EFLGE-101 | 5 | 0.65 | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 2 | 61 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 |
| 74 | -13 | -17.567568 |
|
|
|
| Treatment A | Y | 8 | YEARS | M | CV | 1015 | 6 | DMD-EFLGE | DMD-EFLGE-101 | 6 | 0.65 | N-Terminal ProB-type Natriuretic Peptide (IU/L) | BNPPRONT | 3 | 900 | Visit 6 (1 Year) | 6 | VISIT 1 | 1Jun2023 |
| 40 | 860 | 2150 | >1.0 (IU/L) | 100 | 900 | HIGH | Treatment A | Y | 8 | YEARS | M | LB | 2 |
|
|
Example 2
The dataset above can also be set up to provide multivariate analyses by taking the lab tests of interest, transposing and merging with the ADCVNTPR dataset. In that case, the records from LB are not needed as a row.
The variables transposed are:
Dataset | Value | Where | Variable | Variable Label |
---|
ADCVNTPR | AVAL | PARAMCD ="BNPPRONT" | BNPPRONT | N-Terminal ProB-type Natriuretic Peptide (IU/L) |
ADCVNTPR | CHGCAT1 | PARAMCD ="BNPPRONT" | BNPPRCHG | N-Term ProB-type N Pep Change Category |
Dataset wrap |
---|
|
Rowcaps |
---|
Rows 1-4: | Show the baseline CMR ejection fraction measurements for participant 101 at VISIT 1. | Row 5: | Shows the baseline NTProbTest for participant 101 at VISIT 1. | Rows 6-9: | Show the CMR ejection fraction measurements for participant 101 at VISIT 6. | Row 10: | Shows the NTProbTest for participant 101 at VISIT 6. |
|
Dataset2 |
---|
| Row | STUDYID | USUBJID | ASEQ | BSABASE | BNPPRONT | BNPPRCHG | PARAM | PARAMCD | PARAMN | AVAL | AVISIT | AVISITN | VISIT | ADT | ABLFL | BASE | CHG | PCHG | TRT01P | ITTFL | AGE | AGEU | SEX | SRCDOM | SRCSEQ |
---|
1 | DMD-EFLGE | DMD-EFLGE-101 | 1 | 0.65 | 40 |
| Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 1 | 67 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 67 |
|
| Treatment A | Y | 8 | YEARS | M | CV | 3 | 2 | DMD-EFLGE | DMD-EFLGE-101 | 2 | 0.65 | 40 |
| Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 2 | 74 | Visit 1 (Month 1) | 1 | VISIT 1 | 16May2022 | Y | 74 |
|
| Treatment A | Y | 8 | YEARS | M | CV | 7 | 3 | DMD-EFLGE | DMD-EFLGE-101 | 4 | 0.65 | 900 | >1.0 (IU/L) | Left Ventricular Ejection Fraction, Calculated (%) | LVEFC | 1 | 60 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 |
| 67 | -7 | -10.447761 | Treatment A | Y | 8 | YEARS | M | CV | 11 | 4 | DMD-EFLGE | DMD-EFLGE-101 | 5 | 0.65 | 900 | >1.0 (IU/L) | Right Ventricular Ejection Fraction, Calculated (%) | RVEFC | 2 | 61 | Visit 6 (Month 12) | 6 | VISIT 6 | 01Jun2023 |
| 74 | -13 | -17.567568 | Treatment A | Y | 8 | YEARS | M | CV | 15 |
|
|
Info |
---|
Ejection Fraction - change in ejection fraction, would expect a decline in EF 2-3% per year, would prefer an improvement or no change. Concerning if rapid progression, 10% decline or more, for example.
NTproBNP - % change over a period of time – a decrease would mean improvement, annually is appropriate
SDTM Examples: Basic CMR tests - Systolic Function |
...